MX382516B - Composiciones y metodos para absorcion transmucosa. - Google Patents
Composiciones y metodos para absorcion transmucosa.Info
- Publication number
- MX382516B MX382516B MX2014015436A MX2014015436A MX382516B MX 382516 B MX382516 B MX 382516B MX 2014015436 A MX2014015436 A MX 2014015436A MX 2014015436 A MX2014015436 A MX 2014015436A MX 382516 B MX382516 B MX 382516B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- transmucosal absorption
- agent
- amitryptyline
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000010521 absorption reaction Methods 0.000 title abstract 2
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 abstract 1
- 239000002610 basifying agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 abstract 1
- 229960003572 cyclobenzaprine Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660593P | 2012-06-15 | 2012-06-15 | |
| US201261667774P | 2012-07-03 | 2012-07-03 | |
| US201261725402P | 2012-11-12 | 2012-11-12 | |
| US201361792900P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/046023 WO2013188847A1 (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014015436A MX2014015436A (es) | 2015-07-14 |
| MX382516B true MX382516B (es) | 2025-03-13 |
Family
ID=49758769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014015436A MX382516B (es) | 2012-06-15 | 2013-06-14 | Composiciones y metodos para absorcion transmucosa. |
| MX2021005317A MX2021005317A (es) | 2012-06-15 | 2013-06-14 | Composiciones y métodos para absorción transmucosa. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005317A MX2021005317A (es) | 2012-06-15 | 2013-06-14 | Composiciones y métodos para absorción transmucosa. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20140171515A1 (enExample) |
| EP (1) | EP2861223B1 (enExample) |
| JP (5) | JP6259452B2 (enExample) |
| CN (2) | CN111388430A (enExample) |
| AR (1) | AR092330A1 (enExample) |
| AU (2) | AU2013274003B2 (enExample) |
| BR (1) | BR112014031394B1 (enExample) |
| CA (2) | CA2876902C (enExample) |
| DK (1) | DK2861223T3 (enExample) |
| ES (1) | ES2929133T3 (enExample) |
| HR (1) | HRP20221325T1 (enExample) |
| HU (1) | HUE060175T2 (enExample) |
| IL (1) | IL236268B (enExample) |
| LT (1) | LT2861223T (enExample) |
| MX (2) | MX382516B (enExample) |
| MY (1) | MY194495A (enExample) |
| NZ (2) | NZ631144A (enExample) |
| PL (1) | PL2861223T3 (enExample) |
| PT (1) | PT2861223T (enExample) |
| RS (1) | RS63822B1 (enExample) |
| SG (2) | SG11201408318RA (enExample) |
| SI (1) | SI2861223T1 (enExample) |
| SM (1) | SMT202200436T1 (enExample) |
| TW (3) | TWI590820B (enExample) |
| WO (1) | WO2013188847A1 (enExample) |
| ZA (1) | ZA201500288B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011062614A1 (en) | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| US9636408B2 (en) | 2013-03-15 | 2017-05-02 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| SG10201902203VA (en) | 2014-09-18 | 2019-04-29 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| EP3322412B1 (en) * | 2015-07-15 | 2021-04-07 | Theranexus | Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo |
| US12337063B2 (en) * | 2016-09-02 | 2025-06-24 | University Of Sharjah | Formulation for atropine sulfate rapidly-disintegrating sublingual tablets |
| WO2019014651A1 (en) * | 2017-07-13 | 2019-01-17 | Tonix Pharmaceuticals Holding Corp. | ANALOGUES OF CYCLOBENZAPRINE AND AMITRYPTILENE |
| CN107496355B (zh) * | 2017-08-24 | 2021-04-30 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下喷雾剂及其制备方法 |
| CN107519142B (zh) * | 2017-08-24 | 2021-02-26 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下片及其制备方法 |
| WO2019110723A1 (en) * | 2017-12-08 | 2019-06-13 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation |
| CA3083341C (en) | 2017-12-11 | 2024-05-28 | Tonix Pharma Holdings Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
| CN108721240A (zh) * | 2018-06-08 | 2018-11-02 | 华益药业科技(安徽)有限公司 | 一种25mg阿米替林薄膜包衣片处方和工艺规程 |
| JP7691739B2 (ja) | 2018-08-20 | 2025-06-12 | トニックス ファーマ ホールディングス リミテッド | 急性ストレス障害および外傷後ストレス障害を処置する方法 |
| CA3156118A1 (en) * | 2019-09-30 | 2021-04-08 | Cadila Healthcare Limited | Intranasal pharmaceutical compositions of cyclobenzaprine |
| JP7780447B2 (ja) | 2020-04-08 | 2025-12-04 | トニックス ファーマシューティカルズ ホールディング コーポレイション | 性機能障害のシクロベンザプリン処置 |
| MX2023005899A (es) | 2020-11-20 | 2023-08-16 | TONIX Pharmaceuticals Holding Corp | Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol. |
| EP4255407A1 (en) | 2020-12-07 | 2023-10-11 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for fibromyalgia |
| WO2022170107A2 (en) | 2021-02-04 | 2022-08-11 | Tonix Pharmaceuticals Holding Corp. | An improved method of assessing clinical response in the treatment of ptsd symptoms |
| US20240415789A1 (en) | 2021-10-06 | 2024-12-19 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| US20230414536A1 (en) | 2022-06-21 | 2023-12-28 | Tonix Pharmaceuticals Holding Corp. | CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC) |
| WO2025160302A1 (en) | 2024-01-25 | 2025-07-31 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for acute stress reaction or acute stress disorder |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) * | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| DE69904465T2 (de) * | 1998-05-14 | 2003-10-02 | Alza Corp., Mountain View | Therapie von depressionen |
| JP2003506484A (ja) | 1999-08-13 | 2003-02-18 | ベラ・ファーマシューティカルズ・インコーポレイテッド | 非常に低用量のシクロベンザプリンを使用する睡眠障害の処置または予防するための組成物使用 |
| MXPA02001568A (es) | 1999-08-13 | 2002-07-02 | Vela Pharmaceuticals Inc | Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma. |
| AU2001261744A1 (en) * | 2000-05-19 | 2001-12-03 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| WO2002094229A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of muscle relaxants through an inhalation route |
| CA2515146C (en) * | 2003-02-04 | 2011-12-06 | Chrysalis Technologies Incorporated | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
| US20090117054A1 (en) * | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US20090148532A1 (en) * | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| JP2009079060A (ja) * | 2008-10-15 | 2009-04-16 | Novadel Pharma Inc | 極性または非極性の、バッカルスプレーまたはカプセル |
| US20100266682A1 (en) * | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| US20100247586A1 (en) * | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| WO2011062614A1 (en) * | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) * | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| ITMI20110558A1 (it) * | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| US9636408B2 (en) * | 2013-03-15 | 2017-05-02 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
-
2013
- 2013-06-14 ES ES13804115T patent/ES2929133T3/es active Active
- 2013-06-14 NZ NZ631144A patent/NZ631144A/en unknown
- 2013-06-14 BR BR112014031394-6A patent/BR112014031394B1/pt active IP Right Grant
- 2013-06-14 WO PCT/US2013/046023 patent/WO2013188847A1/en not_active Ceased
- 2013-06-14 TW TW102121267A patent/TWI590820B/zh active
- 2013-06-14 SG SG11201408318RA patent/SG11201408318RA/en unknown
- 2013-06-14 TW TW107117266A patent/TWI683660B/zh active
- 2013-06-14 CA CA2876902A patent/CA2876902C/en active Active
- 2013-06-14 RS RS20221005A patent/RS63822B1/sr unknown
- 2013-06-14 SI SI201332010T patent/SI2861223T1/sl unknown
- 2013-06-14 MX MX2014015436A patent/MX382516B/es unknown
- 2013-06-14 EP EP13804115.7A patent/EP2861223B1/en active Active
- 2013-06-14 AR ARP130102101A patent/AR092330A1/es not_active Application Discontinuation
- 2013-06-14 TW TW106117185A patent/TWI642429B/zh active
- 2013-06-14 HR HRP20221325TT patent/HRP20221325T1/hr unknown
- 2013-06-14 AU AU2013274003A patent/AU2013274003B2/en active Active
- 2013-06-14 CN CN202010024102.2A patent/CN111388430A/zh active Pending
- 2013-06-14 US US13/918,692 patent/US20140171515A1/en not_active Abandoned
- 2013-06-14 CN CN201380039522.6A patent/CN104684550A/zh active Pending
- 2013-06-14 SG SG10201605407TA patent/SG10201605407TA/en unknown
- 2013-06-14 SM SM20220436T patent/SMT202200436T1/it unknown
- 2013-06-14 NZ NZ726488A patent/NZ726488A/en unknown
- 2013-06-14 MX MX2021005317A patent/MX2021005317A/es unknown
- 2013-06-14 CA CA3118913A patent/CA3118913C/en active Active
- 2013-06-14 DK DK13804115.7T patent/DK2861223T3/da active
- 2013-06-14 PL PL13804115.7T patent/PL2861223T3/pl unknown
- 2013-06-14 PT PT138041157T patent/PT2861223T/pt unknown
- 2013-06-14 MY MYPI2014703784A patent/MY194495A/en unknown
- 2013-06-14 HU HUE13804115A patent/HUE060175T2/hu unknown
- 2013-06-14 JP JP2015517469A patent/JP6259452B2/ja active Active
- 2013-06-14 LT LTEPPCT/US2013/046023T patent/LT2861223T/lt unknown
-
2014
- 2014-12-15 IL IL236268A patent/IL236268B/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00288A patent/ZA201500288B/en unknown
-
2017
- 2017-10-02 JP JP2017192713A patent/JP2017222726A/ja not_active Withdrawn
-
2018
- 2018-10-04 AU AU2018241128A patent/AU2018241128B2/en active Active
-
2019
- 2019-05-14 JP JP2019091262A patent/JP2019123757A/ja not_active Withdrawn
-
2021
- 2021-06-16 JP JP2021100154A patent/JP2021138765A/ja not_active Withdrawn
-
2024
- 2024-02-02 JP JP2024014696A patent/JP2024032964A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX382516B (es) | Composiciones y metodos para absorcion transmucosa. | |
| GB201118656D0 (en) | New compounds | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| IN2014DN09434A (enExample) | ||
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MX366899B (es) | Nuevos compuestos. | |
| MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
| PH12013502261A1 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
| GB201209613D0 (en) | New compounds | |
| MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| MX349004B (es) | Nuevos compuestos. | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| PH12016500164B1 (en) | Therapeutically active compounds and their methods of use | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. | |
| MX2015004362A (es) | Derivados de ketamina. | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| MX2015005732A (es) | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. | |
| PY1330684A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. |